Verily Health Raises Series C+ With NVIDIA and CU Healthcare Innovation Fund

Verily Health Inc., a data platform and technology company building AI-enabled precision health solutions, has raised a Series C+ round. The funding was announced on September 9, 2026.

The round includes participation from NVIDIA and the CU Healthcare Innovation Fund. No lead investor was named, and the funding amount was not disclosed.

What Verily Health Does

Verily Health builds AI-enabled precision health solutions on top of a data platform and technology foundation. Its flagship offering, Verily Pre, is described as an AI-native platform for precision health. The company also offers consumer-facing tools, including Verily Me, which is designed to help individuals manage their health.

On the enterprise side, Verily Health provides solutions for clinical research, population health monitoring, and enterprise healthcare customers. A central part of its proposition is harmonizing fragmented data and deploying actionable intelligence into clinical workflows — addressing a persistent problem for healthcare organizations that hold large volumes of disconnected data but struggle to convert it into decisions at the point of care.

The Investor Mix

The participation of NVIDIA and the CU Healthcare Innovation Fund reflects two distinct but complementary perspectives on the company's direction.

NVIDIA's involvement aligns with the compute and infrastructure demands of AI-native healthcare platforms. Training and deploying precision health models at scale requires significant computational resources, and NVIDIA's presence in the round signals a strategic interest in the category.

The CU Healthcare Innovation Fund brings a healthcare system vantage point. Health system innovation funds typically invest with an eye toward operational relevance — how a technology will function inside real clinical and research environments. That perspective is relevant for a company whose stated focus includes deploying intelligence into clinical workflows and supporting clinical research.

Positioning in Precision Health

Verily Health operates in a crowded but expanding segment. Precision health platforms aim to move healthcare from reactive, episodic treatment toward data-driven, individualized care. The challenge for vendors in this space is rarely the availability of data; it is the fragmentation of that data across electronic health records, research systems, devices, and payer sources.

Verily Health's stated approach — harmonizing fragmented data and deploying actionable intelligence — targets that integration problem directly. Its dual focus on enterprise customers and consumer tools (Verily Me) suggests a strategy that spans both the institutional and individual ends of the market.

Clinical research is another area where the company applies its platform. Research organizations face similar data harmonization challenges, and AI-native tooling has become a focal point for improving trial design, patient identification, and monitoring.

Why This Round Matters

A Series C+ raise at this stage indicates continued capital formation as the company scales its platform and commercial footprint. The absence of a disclosed amount and a named lead investor means the round's size and structure are not publicly specified, but the named participants provide a signal about the strategic direction of the business.

For enterprise healthcare customers evaluating precision health vendors, backing from both a compute infrastructure leader and a health system innovation fund can serve as a form of validation — one speaks to technical scalability, the other to clinical and operational fit.

Acquisition Angle

For strategic acquirers, Verily Health presents several attributes worth noting:

AI-native platform: Verily Pre is positioned as an AI-native precision health platform, a category attracting significant strategic interest.
Data harmonization capability: The company's core proposition addresses fragmentation across healthcare data sources, a durable enterprise need.
Dual market reach: Enterprise solutions for clinical research and population health, plus a consumer-facing tool in Verily Me.
Strategic investor base: NVIDIA and the CU Healthcare Innovation Fund bring infrastructure and health system perspectives respectively.
Workflow integration focus: The company's stated aim of deploying actionable intelligence into clinical workflows addresses the last-mile problem that often limits analytics adoption.

What to Watch

With the round announced on September 9, 2026, attention will turn to how Verily Health deploys the capital — whether toward expanding Verily Pre and Verily Me, deepening enterprise and clinical research relationships, or further building out the data platform underpinning its precision health offerings. The involvement of NVIDIA and the CU Healthcare Innovation Fund gives the company both compute-adjacent and provider-adjacent allies as it scales.